In a research report issued today, Oppenheimer analyst Yigal Nochomovitz reiterated a Perform rating on Galena Biopharma (NASDAQ:GALE), following the company’s third-quarter earnings. …
In a research report published this morning, Maxim Group analyst Jason Kolbert maintained a Buy rating on Galena Biopharma (NASDAQ:GALE) with a price …
In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Galena Biopharma (NASDAQ:GALE) with a price target …
In a research note published today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Galena Biopharma (NASDAQ:GALE) with an $8 price target, following the …
In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Galena Biopharma (NASDAQ:GALE) with a $7 price target, as the …
In a research report issued Tuesday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Galena Biopharma (NASDAQ:GALE) with an $8 price …
Galena Biopharma (GALE) announced today the resignation of CEO Mark Ahn and the instillation of COO, Mark Schwartz as its new CEO. In reaction …
